MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy
摘要
The present invention provides novel vaccine formulations for the treatment of cancer antigens. The vaccine comprises a modified MAGE-3 antigen, a NY-ESO-1 antigen, and an adjuvant comprising a saponin and a immunostimulatory oligonucleotide.